All companies
Visit website
PSYONIC
OperatingPSYONIC, Inc.
Healthcare · Biotech · Founded 2015
In-market prosthetic hand that offers users faster and more functional mobility at fraction of the cost
Post-money valuation ⓘ
$66.1M
As of Apr 2024 · from Psyonic Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$3,542,227
Across 2 rounds since 2022
Latest share price
$2.43
Psyonic Common Stock 2 offering price
Financials
FY2020–FY2025 · from SEC filings · hover any figure for its source$674K
−$135K
2020
$653K
−$441K
2021
$1.7M
$102K
2022
$1.9M
−$762K
2023
$3.3M
−$636K
2024
$5.4M
−$1.2M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$674,145
$652,789
$1,655,155
$1,897,869
$3,333,012
$5,350,023
Cost of goods sold
$597,900
$875,986
$810,759
$1,056,665
$1,246,933
$900,689
Gross margin
11%
-34%
51%
44%
63%
83%
Net income
-$134,679
-$441,251
$102,469
-$762,493
-$636,338
-$1,203,216
Taxes paid
$0
$0
$42,417
$0
$8,876
$13,947
Balance sheet
Cash
$389,163
$158,324
$454,419
$801,683
$1,455,176
$1,613,084
Accounts receivable
$15,500
$51,300
$164,025
$279,522
$0
$737,383
Total assets
$558,650
$320,520
$919,057
$2,128,954
$6,569,860
$8,278,321
Short-term debt
$86,381
$9,180
$21,684
$27,694
$132,671
$182,388
Long-term debt
$1,227,500
$1,427,500
$1,427,500
$36,967
$0
$388,356
Total liabilities
$1,313,881
$1,436,680
$1,449,184
$64,661
$132,671
$570,744
Other
Headcount
—
9
13
21
37
21
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$53.0M
post-money
$66.1M
post-money
PSYONIC Common Stock 1
Psyonic Common Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1.1M / $2.7MInvestors 589Post-money $66.1M
Raised $2.5M / $5MInvestors 2,094Post-money $53M
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 4 of 4 annual reports (FY2022–FY2025)
2,094 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 26 filings on EDGARSource: ManualCIK 0001759211Share price $2.43
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.